Clinical course and management of COVID-19 in the era of widespread population immunity

EA Meyerowitz, J Scott, A Richterman, V Male… - Nature Reviews …, 2024 - nature.com
The clinical implications of COVID-19 have changed since SARS-CoV-2 first emerged in
humans. The current high levels of population immunity, due to prior infection and/or …

Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control

S Wang, W Li, Z Wang, W Yang, E Li, X **a… - Signal transduction and …, 2024 - nature.com
To adequately prepare for potential hazards caused by emerging and reemerging infectious
diseases, the WHO has issued a list of high-priority pathogens that are likely to cause future …

COVID-19 annual update: a narrative review

M Biancolella, VL Colona, L Luzzatto, JL Watt… - Human genomics, 2023 - Springer
Three and a half years after the pandemic outbreak, now that WHO has formally declared
that the emergency is over, COVID-19 is still a significant global issue. Here, we focus on …

Remdesivir: a review in COVID-19

HA Blair - Drugs, 2023 - Springer
Remdesivir (Veklury®), a nucleotide analogue prodrug with broad-spectrum antiviral activity,
is approved for the treatment of coronavirus disease 2019 (COVID-19), the illness caused by …

National Institutes of Health COVID-19 treatment guidelines panel: perspectives and lessons learned

RM Gulick, AK Pau, E Daar, L Evans… - Annals of Internal …, 2024 - acpjournals.org
Description: In March 2020, the White House Coronavirus Task Force determined that
clinicians in the United States needed expert treatment guidelines to optimally manage …

Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review

C Fernández-de-Las-Peñas, J Torres-Macho… - Infection, 2024 - Springer
Purpose Preliminary evidence suggests a potential effect of antiviral medication used during
the acute COVID-19 phase for preventing long-COVID. This review investigates if having …

The efficacy of antivirals, corticosteroids, and mAbs as acute COVID treatments in reducing the incidence of long COVID: a systematic review and meta-analysis

G Sun, K Lin, J Ai, W Zhang - Clinical Microbiology and Infection, 2024 - Elsevier
Background Whether treatment during acute COVID results in protective efficacy against
long COVID incidence remains unclear. Objectives To assess the relationship between …

Management of vulnerable patients hospitalized for COVID-19 with remdesivir: a retrospective comparative effectiveness study of mortality in US hospitals

E Mozaffari, A Chandak, M Berry, PE Sax… - Clinical Infectious …, 2024 - academic.oup.com
Abstract Background Coronavirus disease 2019 (COVID-19) remains a major public health
concern, with continued resurgences of cases and substantial risk of mortality for …

Expert consensus: main risk factors for poor prognosis in COVID-19 and the implications for targeted measures against SARS-CoV-2

FJ Candel, P Barreiro, M Salavert, A Cabello… - Viruses, 2023 - mdpi.com
The clinical evolution of patients infected with the Severe Acute Respiratory Coronavirus
type 2 (SARS-CoV-2) depends on the complex interplay between viral and host factors. The …

Global landscape of COVID-19 research: a visualization analysis of randomized clinical trials

SH Zyoud - Clinical and Experimental Medicine, 2024 - Springer
The emergence of COVID-19 in 2019 has resulted in a significant global health crisis.
Consequently, extensive research was published to understand and mitigate the disease. In …